Abstract
Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss. There is also evidence of potential compensatory responses in DS that benefit the brain and delay the onset of dementia after there is sufficient neuropathology for a diagnosis of AD. This review describes some of the existing literature and also highlights gaps in our knowledge regarding AD neuropathology in DS. It will be critical in the future to develop networked brain banks with standardized collection procedures to fully characterize the regional and temporal pathological events associated with aging in DS. As more information is acquired regarding AD evolution in DS, there will be opportunities to develop interventions that are age-appropriate to delay AD in DS.
Keywords: Beta-amyloid, neurofibrillary tangles, neuroinflammation, oxidative damage, posttranslational modifications, senile plaques, trisomy 21, vascular pathology, white matter damage.
Current Alzheimer Research
Title:Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Volume: 13 Issue: 1
Author(s): Elizabeth Head, Ira T. Lott, Donna M. Wilcock and Cynthia A. Lemere
Affiliation:
Keywords: Beta-amyloid, neurofibrillary tangles, neuroinflammation, oxidative damage, posttranslational modifications, senile plaques, trisomy 21, vascular pathology, white matter damage.
Abstract: Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss. There is also evidence of potential compensatory responses in DS that benefit the brain and delay the onset of dementia after there is sufficient neuropathology for a diagnosis of AD. This review describes some of the existing literature and also highlights gaps in our knowledge regarding AD neuropathology in DS. It will be critical in the future to develop networked brain banks with standardized collection procedures to fully characterize the regional and temporal pathological events associated with aging in DS. As more information is acquired regarding AD evolution in DS, there will be opportunities to develop interventions that are age-appropriate to delay AD in DS.
Export Options
About this article
Cite this article as:
Head Elizabeth, T. Lott Ira, M. Wilcock Donna and A. Lemere Cynthia, Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology, Current Alzheimer Research 2016; 13 (1) . https://dx.doi.org/10.2174/1567205012666151020114607
DOI https://dx.doi.org/10.2174/1567205012666151020114607 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acid Sensing Ion Channels and Acid Nociception
Current Pharmaceutical Design Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases
Current Pharmaceutical Design The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy
Current Medicinal Chemistry Mechanisms of Cell Signaling and Inflammation in Alzheimers Disease
Current Drug Targets - Inflammation & Allergy The Cytokine Network in HIV Infection
Current Molecular Medicine Peptide Sequence Prediction Supported by Correlation-Associated Networks in Human Cerebrospinal Fluid
Combinatorial Chemistry & High Throughput Screening Repetitive Transcranial Magnetic Stimulation Reverses Aβ1–42-induced Dysfunction in Gamma Oscillation during Working Memory
Current Alzheimer Research High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer’s Disease
Current Alzheimer Research A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Current Alzheimer Research Mitochondria and Synaptic Plasticity in the Mature and Aging Nervous System
Current Neuropharmacology Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science Plasma Gelsolin: Function, Prognostic Value, and Potential Therapeutic Use
Current Protein & Peptide Science Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart
Current Pharmaceutical Design Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets